Mangrove Partners’s CureVac CVAC Stock Holding History

Mangrove Partners’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,200	Closed	-$1.1M	–	518
2021 Q3	$1.1M	Buy	+20,200	New	+$1.22M	0.1%	290

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Mangrove Partners's CVAC Position: Q4 2021 in Review

Mangrove Partners sold out of CureVac (CVAC) in Q4 2021, closing a stake of 20,200 shares — an estimated $1.1M sold.

Mangrove Partners first reported a position in CVAC in Q3 2021 and held it in 1 quarter. The position peaked at $1.1M in Q3 2021. 103 funds tracked by Wall St. Rank hold CVAC as of Q4 2021.

Mangrove Partners reported no remaining CureVac position as of Q4 2021 after selling out during the quarter.
Mangrove Partners sold 20,200 CureVac shares in Q4 2021, an estimated $1.1M.
Mangrove Partners first reported a position in CureVac in Q3 2021 and held it in 1 quarter.
Mangrove Partners's CureVac position peaked at $1.1M in Q3 2021.
103 funds tracked by Wall St. Rank held CureVac as of Q4 2021.

Based on Mangrove Partners's 13F filing for Q4 2021, filed 14 Feb 2022.